INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 46 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $88,000 | -35.3% | 117,000 | -31.2% | 0.00% | – |
Q1 2020 | $136,000 | -20.5% | 170,000 | 0.0% | 0.00% | -100.0% |
Q4 2019 | $171,000 | +17.1% | 170,000 | 0.0% | 0.00% | – |
Q3 2019 | $146,000 | -3.9% | 170,000 | 0.0% | 0.00% | – |
Q2 2019 | $152,000 | -9.5% | 170,000 | 0.0% | 0.00% | -100.0% |
Q1 2019 | $168,000 | – | 170,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Man Investments (CH) AG | 3,300,000 | $2,640,000 | 2.48% |
SYMPHONY ASSET MANAGEMENT LLC | 14,000,000 | $11,200,000 | 1.14% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 36,000,000 | $28,879,000 | 1.14% |
Opera Trading Capital | 5,500,000 | $4,344,000 | 0.89% |
MACKAY SHIELDS LLC | 17,789,000 | $14,221,000 | 0.52% |
TENOR CAPITAL MANAGEMENT Co., L.P. | 6,000,000 | $4,918,000 | 0.37% |
ADVENT CAPITAL MANAGEMENT /DE/ | 24,415,000 | $19,539,000 | 0.37% |
OAKTREE CAPITAL MANAGEMENT LP | 28,415,000 | $22,732,000 | 0.36% |
GLG Partners LP | 8,700,000 | $6,960,000 | 0.33% |
HIGHFIELDS CAPITAL MANAGEMENT LP | 42,285,000 | $33,828,000 | 0.28% |